Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 1:12:694872.
doi: 10.3389/fneur.2021.694872. eCollection 2021.

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Affiliations
Review

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Brent Bluett et al. Front Neurol. .

Abstract

Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes. CBS presents with prominent and usually asymmetric dystonia, apraxia, myoclonus, pyramidal signs, and cortical sensory loss. The symptoms and deficits of PSP and CBS are amenable to a variety of treatment strategies but most physicians, including many neurologists, are reluctant to care for patients with these conditions because of unfamiliarity with their multiplicity of interacting symptoms and deficits. CurePSP, the organization devoted to support, research, and education for PSP and CBS, created its CurePSP Centers of Care network in North America in 2017 to improve patient access to clinical expertise and develop collaborations. The directors of the 25 centers have created this consensus document outlining best practices in the management of PSP and CBS. They formed a writing committee for each of 12 sub-topics. A 4-member Steering Committee collated and edited the contributions. The result was returned to the entire cohort of authors for further comments, which were considered for incorporation by the Steering Committee. The authors hope that this publication will serve as a convenient guide for all clinicians caring for patients with PSP and CBS and that it will improve care for patients with these devastating but manageable disorders.

Keywords: CurePSP; consensus; corticobasal syndrome; management; palliative; progressive supranuclear palsy; symptomatic; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. . Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. (1996) 46:922–30. 10.1212/WNL.46.4.922 - DOI - PubMed
    1. Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, et al. . Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. (2017) 32:995–1005. 10.1002/mds.27034 - DOI - PMC - PubMed
    1. Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. . Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. (2017) 32:853–64. 10.1002/mds.26987 - DOI - PMC - PubMed
    1. Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, et al. . Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. (2002) 17:1255–64. 10.1002/mds.10211 - DOI - PubMed
    1. Xie T, Kang UJ, Kuo S-H, Poulopoulos M, Greene P, Fahn S. Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. NPJ Parkinsons Dis. (2015) 1:1–6. 10.1038/npjparkd.2015.7 - DOI - PMC - PubMed